Newsroom

Actions

170320 PR JP VI BIOFLOW IV EN

Actions

Japan Circulation Society 2017: Orsiro Drug-Eluting Coronary Stent Convinces in BIOFLOW-IV Study

Non-Inferiority of Orsiro vs. Xience Proven with Target Vessel Failure of 3.5% and 4.2%, respectively1






Please contact us if you require further information.

${loading}